Three things to take away
What is the outlook for the UK life sciences sector and how is the productivity crisis impacting growth prospects
What are the three future risk areas life science firms should be aware of in 2023
What can life science firms do to boost growth using digitalization, research, recruitment and regulation
Post-pandemic, the outlook for the UK’s diverse and established life sciences sector is broadly positive, fitting into post-Brexit plans to make the UK an innovation power player while seeing lesser effects from economic downturn than other sectors.
However, post-Brexit revisions take effect on the regulatory front, creating an increased compliance burden. There are also questions about the UK’s ability to compete funding-wise with its EU neighbours alongside the sector’s poor productivity performance potentially impairing price competitiveness and profit margins.
What is the outlook for the UK life sciences sector and how is the productivity crisis impacting growth prospects
What are the three future risk areas life science firms should be aware of in 2023
What can life science firms do to boost growth using digitalization, research, recruitment and regulation
Post-pandemic, the outlook for the UK’s diverse and established life sciences sector is broadly positive, fitting into post-Brexit plans to make the UK an innovation power player while seeing lesser effects from economic downturn than other sectors.
However, post-Brexit revisions take effect on the regulatory front, creating an increased compliance burden. There are also questions about the UK’s ability to compete funding-wise with its EU neighbours alongside the sector’s poor productivity performance potentially impairing price competitiveness and profit margins.
Building Supply Chain Resilience
Understand and manage risk in your supply chain
More like this
Sign-up to be notified about future articles from the Sector Resilience Series, and other thoughts, reports or insights from QBE.
Subscribe now
